58864
document
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer . We aimed to assess the efficacy and safety of concurrent capecitabine and cisplatin over concurrent cisplatin and 5-flurouracil ( 5-FU ) in locally advanced squamous cell carcinoma of the head and neck . One hundred and fifty-three patients ( all of whom had stage III or IV unresectable disease with no distant metastases and who had received two cycles of taxol and cisplatin chemotherapy ) were randomly assigned to receive either concurrent cisplatin ( 75 mg/m ( 2 ) in day 1 and 2 ) and 5-FU ( 750 mg/m ( 2 ) in day 1 , 2 , and 3 ) from the first day of radiotherapy at an interval of 3 weeks ( Arm I ) or cisplatin ( 75 mg/m ( 2 ) in day 1 and 2 ) and capecitabine ( 750 mg/m ( 2 ) in two divided doses from day 1-14 ) from the first day of radiotherapy at a 3-week interval ( Arm II ) . Results showed that patients in Arm II had a significantly better rate of complete response , fewer nodes , and better overall response compared to those in Arm I . The two groups had a similar 3-year disease-free survival , progression free survival , and overall survival , i.e . they did not differ significantly . Variables indicating the quality of life of the two groups were compared . Patients in Arm II had a significantly higher quality of life compared to those in Arm I . The two groups had similar treatment-related acute and late toxicity , i.e . they did not differ significantly . These results have thoroughly substantiated the contention that concurrent chemoradiation with capecitabine and cisplatin may be regarded as an effective and well-tolerated regimen in the treatment of the patients with locally advanced head and neck cancer .
58865
Intervention_Pharmacological
capecitabine and cisplatin
58866
Intervention_Pharmacological
concurrent cisplatin and 5-flurouracil
58867
Intervention_Pharmacological
capecitabine and cisplatin
58868
Intervention_Pharmacological
concurrent cisplatin and 5-flurouracil ( 5-FU )
58869
Intervention_Pharmacological
taxol and cisplatin chemotherapy
58870
Intervention_Pharmacological
concurrent cisplatin
58871
Intervention_Pharmacological
and 5-FU
58872
Intervention_Pharmacological
cisplatin
58873
Intervention_Pharmacological
capecitabine
58874
Intervention_Pharmacological
capecitabine and cisplatin
58875
Outcome_Physical
better rate of complete response
58876
Outcome_Physical
fewer nodes
58877
Outcome_Physical
better overall response
58878
Outcome_Mortality
3-year disease-free survival
58879
Outcome_Mortality
progression free survival
58880
Outcome_Mortality
overall survival
58881
Outcome_Physical
quality of life
58882
Outcome_Physical
quality of life
58883
Outcome_Adverse-effects
acute and late toxicity
58884
Participant_Condition
locally advanced squamous cell head and neck cancer
58885
Participant_Condition
carcinoma
58886
Participant_Sample-size
One hundred and fifty-three
58887
Participant_Condition
unresectable disease
58888
Participant_Condition
locally advanced head and neck cancer